| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KNTE | Common Stock | Other | +1,100,000 | +126% | 1,975,001 | 17 Feb 2023 | See Footnote | F1, F2, F3 | ||
| holding | KNTE | Common Stock | 9,671,643 | 17 Feb 2023 | See Footnote | F4 | |||||
| holding | KNTE | Common Stock | 291,667 | 17 Feb 2023 | See Footnote | F5 |
| Id | Content |
|---|---|
| F1 | On February 17, 2023, the Issuer completed the acquisition of Kinnjiu Biompharma, Inc. (the "Kinnjiu Acquisition"). Foresite Capital Fund V, L.P. ("Fund V") was a shareholder of Kinnjiu Biompharma, Inc. and, as a result of the Kinnjiu Acquisition, Fund V received a combination of cash and 1,100,000 shares of the Issuer's Common Stock. |
| F2 | Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757. |
| F3 | The shares are owned directly by Fund V. Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| F4 | The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum, in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| F5 | The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
This Form 4 is one of two Form 4s filed on the date hereof in respect of these transactions. The Reporting Person for the other Form 4 is James B. Tananbaum.